The new Engitix-CSO, Christopher Stevenson, will be responsible for leading the scientific and translational strategy, and for leading Engitx' R&D Pharma partnerships. Stevenson joins from Johnson & Johnson, where he most recently served as Vice President, Global Head of Pharmaceutical Sciences for Interventional Oncology. In this role he was responsible for building a team to support discovery through early development programs and delivering a portfolio of clinical-stage assets, which included multiple cancer immunotherapies and the licensing of NBTXR3 from Nanobiotix. Prior to this, Stevenson headed discovery and tr anslational biology units at Respivert, Novartis and Roche.He received his Doctorate and Bachelor of Science degrees from the University of California, Santa Barbara, USA.